FDA RECALLS & COURT ACTIONS: Oct. 27, 1993
Executive Summary
CLASS II -- DECLOMYCIN HCL CAPSULES 150 mg, in bottles of 100, Rx antibiotic. Recall number: D-010-4. Control numbers: 280-446 EXP March 1995, 297-437 EXP June 1995. Manufacturer: LederLe Labs, Pearl River, New York. Recalled by: Manufacturer, by letter Sept. 30, 1993. Firm-initiated recall ongoing. Distribution: California, Illinois, Pennsylvania, Texas, Puerto Rico; 10,396 bottles were distributed. Reason: Product does not meet dissolution specifications through expiration date. CLASS II -- TRENTAL (PENTOXIFYLiNE) 400 MG TABLETS In bottles of 100, Rx indicated for the treatment of patients with intermittent claudication. Recall number: D-009-4. Lot Number/Expiration Date: 078-566-1/April 1994; 078-568-1/April 1994; 078-569-1/April 1994; 078-572-1/April 1994; 078-2-04-2/November 1994; 078-201-2/November 1994; 078-250-Z/November 1994; 078-244- 2/November 1994; 078-416-2/January 1995; 078-423-Z/February 1995; 078-424-2/February 1995; 078-428-2/February 1995; 078-438-Z/February 1995; 078-445-2/February 1995; 078-449-2/February 1995; 078-464- Z/February 1995; 078-465-2/February 1995; 078-466-2/February 1995; 078-468-2/February 1995; 078-469-2/February 1995; 078-470-2/February 1995; 078-476-2/February 1995; 078-477-Z/February 1995; 078-480- 2/March 1995; 078-481-2/March 1995; 078-482-2/March 1995; 078-484- Z/March 1995; 078-485-2/March 1995; 078-486-2/March 1995; 078-487- 2/March 1995; 078-489-2/March 1995; 078-735-2/April 1995; 078-740- 2/April 1995. Note: The 2 lot numbers 078-201-2 and 078-244-2, are the 2 lot numbers included in the Aug. 30, 1993 recall extension. Manufacturer: Hoechst-Roussel Pharmaceuticals, Inc., Somerville, New Jersey. Recalled by: Manufacturer, by letters of June 22, 1993 and Aug. 30, 1993. Firm-initiated recall complete. Distribution: Nationwide. Reason: Product does not meet sustained-release specifications.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth